Literature DB >> 21621998

Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines.

Austin Chen1, Louis-Charles Campeau, Elizabeth Cauchon, Amandine Chefson, Yves Ducharme, Daniel Dubé, Jean-Pierre Falgueyret, Pierre-André Fournier, Sébastien Gagné, Erich Grimm, Yongxin Han, Robert Houle, Jing-Qi Huang, Patrick Lacombe, Sébastien Laliberté, Jean-François Lévesque, Susana Liu, Dwight MacDonald, Bruce Mackay, Dan McKay, M David Percival, Chris Regan, Hillary Regan, René St-Jacques, Sylvie Toulmond.   

Abstract

An SAR campaign aimed at decreasing the overall lipophilicity of renin inhibitors such as 1 is described herein. It was found that replacement of the northern appendage in 1 with an N-methyl pyridone and subsequent re-optimization of the benzyl amide handle afforded compounds with in vitro and in vivo profiles suitable for further profiling. An unexpected CV toxicity in dogs observed with compound 20 led to the employment of a time and resource sparing rodent model for in vivo screening of key compounds. This culminated in the identification of compound 31 as an optimized renin inhibitor.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21621998     DOI: 10.1016/j.bmcl.2011.05.013

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

1.  Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor.

Authors:  Yuji Nakamura; Teppei Fujimoto; Yasuyuki Ogawa; Chie Sugita; Shojiro Miyazaki; Kazuhiko Tamaki; Mizuki Takahashi; Yumi Matsui; Takahiro Nagayama; Kenichi Manabe; Makoto Mizuno; Noriko Masubuchi; Katsuyoshi Chiba; Takahide Nishi
Journal:  ACS Med Chem Lett       Date:  2012-08-18       Impact factor: 4.345

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.